



Article 2-Aryl-6-Polyfluoroalkyl-4-Pyrones as Promising R^F-Building-Blocks: Synthesis and Application for Construction of Fluorinated Azaheterocycles

Sergey A. Usachev ^(D), Diana I. Nigamatova, Daria K. Mysik, Nikita A. Naumov, Dmitrii L. Obydennov ^(D) and Vyacheslav Y. Sosnovskikh *^(D)

Institute of Natural Sciences and Mathematics, Ural Federal University, 51 Lenina Ave., 620000 Ekaterinburg, Russia; s.a.usachev@urfu.ru (S.A.U.); nigamatova.di@yandex.ru (D.I.N.); mysik.darya@gmail.com (D.K.M.); niquezor@yandex.ru (N.A.N.); dobydennov@mail.ru (D.L.O.) * Correspondence: vy.sosnovskikh@urfu.ru; Tel.: +7-343-3899597

Abstract: A convenient and general method for the direct synthesis of 2-aryl-6-(trifluoromethyl)-4pyrones and 2-aryl-5-bromo-6-(trifluoromethyl)-4-pyrones has been developed on the basis of *one-pot* oxidative cyclization of (*E*)-6-aryl-1,1,1-trifluorohex-5-ene-2,4-diones via a bromination/dehydrobromination approach. This strategy was also applied for the preparation of 2-phenyl-6-polyfluoroalkyl-4pyrones and their 5-bromo derivatives. Conditions of chemoselective enediones bromination were found and the key intermediates of the cyclization of bromo-derivatives to 4-pyrones were characterized. Synthetic application of the prepared 4-pyrones has been demonstrated for the construction of biologically important CF₃-bearing azaheterocycles, such as pyrazoles, pyridones, and triazoles.

Keywords: β-diketones; 4-pyrones; fluorinated heterocycles; regioselective bromination

1. Introduction

4-Pyrone unit is an important heterocyclic motif, which is frequently present in numerous natural products that exhibit a wide range of important biological activities [1–5] and medicines, such as phenoxan [5] (Figure 1). Mainly, pyrones are of interest as useful and versatile building-blocks for the synthesis of valuable molecules [6–9], including pharmaceuticals [10] and pyranic fluorophores [11]. Pyrones as polyelectrophilic substrates and cyclic enone are able to react regioselectively with nucleophiles to undergo ring-opening transformations affording azaheterocycles [12–16]. The formation of the product is usually very sensitive to the reaction conditions (acidity, solvent polarity, temperature) that allows divergent syntheses on the basis of 4-pyrones [15,16].

It is known that fluorine-bearing compounds are of considerable interest for medicinal chemistry and agrochemistry [17]. The search for readily available and highly functionalized fluorinated building blocks for the construction of complex molecules is an important task for the synthesis of new bioactive substances.

To date considerable attention has been focused on 4-pyrones bearing the electronwithdrawing R^F group, which demonstrate higher reactivity with high chemoselectivity of processes compared to non-fluorinated analogs [17,18]. The ring-opening reactions of 2-R^F-4-pyrones can be applied for the preparation of a wide range of trifluoromethylated azaheterocycles, such as indoles, regioisomeric pyrazoles, pyridines, benzodiazepines etc., [14,16–18].

Despite the promising synthetic utility of CF₃-bearing 4-pyrones, they remain to be hard-to-reach compounds [17,18]. The methods for the construction of 4-pyrones are actively developed, and in the literature there are three general approaches for the synthesis of 2-R^F-4-pyrones based on (i) cyclization of tricarbonyl compounds or their derivatives prepared via Claisen condensation [19–22], (ii) cycloadditions of ketenes [23–25], and



Citation: Usachev, S.A.; Nigamatova, D.I.; Mysik, D.K.; Naumov, N.A.; Obydennov, D.L.; Sosnovskikh, V.Y. 2-Aryl-6-Polyfluoroalkyl-4-Pyrones as Promising R^F-Building-Blocks: Synthesis and Application for Construction of Fluorinated Azaheterocycles. *Molecules* **2021**, *26*, 4415. https://doi.org/10.3390/ molecules26154415

Academic Editor: Viktor O. Iaroshenko

Received: 28 June 2021 Accepted: 19 July 2021 Published: 21 July 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). (iii) modification of substituted 2-R^F-4-pyrones (usually for carboxylic acid derivatives) via side-chain transformations [26] (Scheme 1). However, there are usually some limitations connected with the narrow scope of obtained pyrones, variation of the nature of the substituents in several positions of the pyrone ring, and preparation of 4-pyrones bearing long-chain polyfluoroakyl substituents.



Figure 1. Some representative examples of biologically important arylated 4-pyrones.

via 1,3,5-triketone formation [20, 21]



via ketene formation [23]



Scheme 1. The main strategies in the synthesis of arylated 2-R^F-4-pyrones [20,21,23].

Inspired by the chemistry of 2-CF₃-chromones (benzopyrones) [27] and 2-CF₃-4pyrones [18], we decided to find an approach for the construction of a range of novel arylated 2-R^F-4-pyrones as useful building-blocks for the preparation of fluorinated heterocycles. The number of 2-aryl-6-(trifluoromethyl)-4-pyrones described in the literature is limited by several examples [23–25], and there is also the publication regarding the reaction of 2-phenyl-6-(trifluoromethyl)-4-pyrone and salicylic aldehyde with no mention of its synthesis [28]. Thus, there is no general method for the synthesis of the fluorinated 2-aryl-4-pyrones at the moment. Recently, methods for the preparation of pyrones based on the cyclization of acetylenyl-1,3-diketones have been actively developed [29–33], which allows the switchable preparation of 4-pyrones or furanones. Similar approach is the use of dibromo derivatives, which can react as synthetic equivalents of acetylenyl-1,3-diketones and undergo dehydrobromination reactions under basic conditions [34–37]. This method was applied for the preparation of 2-aryl-4-pyrones bearing the methyl and carboethoxy substituents. However, low selectivity of the bromination reaction of the starting enediones, difficult isolation of intermediate products, low yields, and very high sensitivity to the nature of the substituents strongly restrict its utilization.

The chemical properties of 6-aryl-1,1,1-trifluorohex-5-ene-2,4-diones remain unexplored, but they can be considered as a platform for the preparation of new fluorinated compounds [38–41]. The presence of several functional groups (conjugated double bonds and the diketone moiety) in their molecules makes them attractive and useful tools in organic synthesis. The introduction of the strong electron-withdrawing trifluoromethyl group can lead to a change in the chemoselectivity of the bromination reaction of 6-aryl-1,1,1-trifluorohex-5-ene-2,4-diones in comparison with non-fluorinated analogs and to changes in the cyclization step due to the ability of this group to stabilize cyclic and hemiacetal forms [17].

In the present work, we have developed a general method for the preparation of 2-aryl-6-polyfluoroalkyl-4-pyrones and their 3-bromo derivatives based on *one-pot* cyclization through the stage of bromination/dehydrobromination of enediones. The synthetic potential of the pyrones was demonstrated on the example of regioselective reactions with N-nucleophiles.

2. Results and Discussion

We started our research with the preparation of fluorinated enediones **2** based on the condensation reaction of 4-aryl-3-buten-2-ones **1** with ethyl polyfluoroalkanoates in the presence of sodium hydride in diethyl ether at room temperature or lithium hydride in benzene under reflux (Scheme 2, Table 1). Both methods were comparably effective, and CF₃-bearing products **2a**–**i** were obtained in 51–92% yields. Compounds **2a**,**f**–**h** have been described in the literature, but they were prepared by other methods [38–41]. Besides, this approach was applied for the preparation of polyfluorinated enediones **2j–l** in 43–51%.



Scheme 2. Synthesis of enediones 2 via Claisen condensation.

We first focused on the bromination of CF₃-containing compounds **2a–i** in order to obtain active intermediates and to develop a general method for the construction of pyrones based on enediones **2**. Both the double bond and the diketone moiety in 6-aryl-1,1,1-trifluorohex-5-ene-2,4-diones **2** can undergo an electrophilic attack of bromine. To estimate the influence of conditions on conversion, the chemo- and stereoselectivity (see detailed data in Supplementary Materials), the bromination reaction was examined for compound **2b** bearing the *para*-fluorophenyl substituent (Scheme 3, Table 2). It was shown that the most active fragment is the double bond that leads to the initial formation of dibromo derivative **3b**, and no product of initial attack only at the methylene group of the diketone moiety was found. At the same time, compounds **3** due to the absence of conjugation were able to react with Br₂ by the diketone moiety at a comparable rate with the starting enediones **2** giving tribromo derivatives **4**.

Enedione	Ar	$\mathbf{R}^{\mathbf{F}}$	Yield, %	Mp, °C
2a	Ph	CF ₃	75	56–58
2b	$4-FC_6H_4$	CF ₃	64	83-84
2c	$4-ClC_6H_4$	CF ₃	60	92–93
2d	$4-BrC_6H_4$	CF ₃	92	86-87
2e	$3-O_2NC_6H_4$	CF ₃	51 ^a	119-120
2f	$4 - MeC_6H_4$	CF ₃	65	61–62
2g	$4-MeOC_6H_4$	CF ₃	81	104-105
2h	4-Me ₂ NC ₆ H ₄	CF ₃	67	79-80
2i	$2-C_4H_3S$	CF ₃	84	94–95
2j	Ph	CF ₂ H	43	85-87
2k	Ph	$H(CF_2)_2$	43	Liq.
21	Ph	$H(CF_2)_4$	51	Liq.

Table 1. The scope of prepared enediones 2.

^a Lithium hydride in benzene under reflux.



Scheme 3. Reaction of enediones 2 with Br₂.

Table 2. Selectivity of bromination of enediones 2 a.

№	Ar	Enedione	Br ₂ Equiv.	Solvent	2:3:4 Ratio ^b
1	$4-FC_6H_4$	2b	1.0	AcOH ^e	74:(7 + 2 ^c):(16 + 1 ^c)
2	$4-FC_6H_4$	2b	1.0	CH_2Cl_2	42:(37 + 2 ^c):19
3	$4-FC_6H_4$	2b	2.5	CH_2Cl_2	0:7 ^c :93
4	$4-FC_6H_4$	2b	1.0	t-BuOMe	17:(31 + 4 ^c):(39 + 9 ^c)
5	$4-FC_6H_4$	2b	1.0	dioxane	29:65:6
6	$4-FC_6H_4$	2b	1.0	CS_2	$25:(65 + 2^{c}):(7 + 1^{c})$
7	$4-FC_6H_4$	2b	1.0	C_6H_6	12:78:10
8	$4-FC_6H_4$	2b	1.2	C_6H_6	$0:(75 + 4^{\circ}):(19 + 2^{\circ})$
9	$4-FC_6H_4$	2b	2.2	C_6H_6	$0:(46 + 10^{\circ}):(33 + 11^{\circ})$
10	$4-MeOC_6H_4$	2g	1.0	C_6H_6	3:75:22
11	$2-C_4H_3S$	2i	1.0	C_6H_6	9:(80 + 8 ^d):3
12	$4-ClC_6H_4$	2c	1.0	C_6H_6	62:(10 + 3 ^c):25
13	$3-O_2NC_6H_4$	2e	1.0	C_6H_6	55:(14 + 2 ^c):(26 + 3 ^c)
14	Ph	2a	1.0	C_6H_6	62:24:14
15	Ph	2a	1.0	CH_2Cl_2	0:(86 + 2 ^c):12

 a A solution of Br₂ was added to enedione **2** under cooling on an ice-bath. The reaction mixture was stirred at room temperature for 15 h. ^b Based on the ¹⁹F and ¹H NMR spectra. ^c Cyclized to dihydropyrone. ^d A product of dehydrobromination was spontaneously formed. ^e Br₂ was added at room temperature.

When 1 equiv. of bromine was used, incomplete conversion was usually observed, accompanied by the formation of tribromo derivative **4b**. Bromination in acetic acid gave low conversion (26%) and predominant formation of the tribromo derivative (**3b**:**4b** = 9:17) (entry 1). Carrying out the reaction in aprotic polar solvents CH_2Cl_2 and *t*-BuOMe made it possible to increase the conversion to 58 and 83%, respectively, but the selectivity turned out to be low (entries 2,4). The use of non-polar aprotic solvents (dioxane, CS₂) led to the improved **3b**:**4b** ratio and 71–75% conversion (entries 5,6). When the reaction was carried out in benzene, the highest conversion (88%), the highest NMR yield of **3b**, and the good selectivity of the reaction were found (**3b**:**4b** = 78:10) (entry 7). A slight increase in the amount of bromine (up to 1.2 equiv.) led to a decrease in selectivity (**3b**:**4b** = 79:21), although the starting compound **2b** was not detected at all (entry 8).

Further investigation showed that the bromination reaction is very sensitive to the nature of the substituents in the aromatic ring (Scheme 3, Table 2, and Table S1 in Supplementary Materials). Thus, the reaction proceeded with the highest selectivity with one

equivalent of bromine in benzene for compounds bearing moderate and good π -donors (4-MeO, 4-F or Ar = 2-Th) (entries 7,10,11). The introduction of electron-withdrawing substituents (4-Cl, 3-NO₂) into the aromatic ring decreased the selectivity of the transformation for compounds **2c**,**e** due to incomplete conversion and the formation of tribromo derivatives **4** as major products (entries 12,13). Even in the case of enedione **2a** (Ar = Ph), selectivity and conversion of bromination in benzene turned out to be poor (entry 14), however, the use of CH₂Cl₂ as a solvent improved the selectivity and the conversion (entry 15). The introduction of the strong electron-donating substituent (4-Me₂N) led to preferential bromination at the aromatic ring rather than at the double bond followed by cyclization because of basic properties of the substituent (Scheme S1 in Supplementary Materials). It should be noted that, in all cases, compounds **3** were formed as a sole *anti*-dibromo diastereoisomer according to the classical concept of electrophilic addition of bromine to alkenes via the cyclic bromonium cation [42].

Further, we decided to develop a procedure for the bromination of both fragments of enediones **2** simultaneously for the selective preparation of tribromo derivatives **4**. The reaction of enedione **2b** with an excess of bromine (2.2 equiv.) in benzene gave products with low selectivity (**3b**:**4b** = 56:44) (Table 2, entry 9). Moreover, significant amounts of corresponding dihydropyrones were formed as a result of spontaneous acid-catalyzed cyclization. One of the highest yields of compound **4b** in reaction with 1 equiv. of bromine was observed in dichloromethane (entry 2). The use of bromine (2.5 equiv.) in this solvent led to the almost selective formation of tribromo derivative **4b** as a mixture of two diastereoisomers in a ratio of 80:20 (entry 3).

Although the reaction of enediones **2** with Br₂ gave dibromo derivatives **3** or tribromo derivatives **4** as major products, we did not usually isolate them in pure form to avoid additional losses because of their ability to cyclize and high reactivity. But for several cases, these compounds were obtained as a single isomer by recrystallization. The reaction of enediones **2a**,**g** with one equivalent of bromine in acetic acid made it possible to obtain dibromo derivatives **3a** and **3g** in 71 and 28% yields, respectively (Scheme 4).



Scheme 4. Preparative bromination of enediones 2.

The reaction of chloro-substituted enedione 2c with an excess of bromine (2.5 equiv.) in CH₂Cl₂ led to tribromo derivative 4c (dr = 80:20) smoothly in 82% yield. Compound 4c in pure crystalline form prepared by recrystallization from hexane is stable and can be stored for a long time without changes.

The structure of tribromo derivatives **4** was established on the basis of elemental analysis data and ¹H and ¹⁹F NMR spectra (Table S3 in Supplementary Materials). In the ¹H NMR spectra of these compounds in CDCl₃, two singlets of the diastereotopic OH groups were observed at δ 4.06–4.46 and 4.62–4.79 ppm. The ¹⁹F NMR spectra exhibit the CF₃ group at δ 79.7–79.9 ppm indicating its location at the saturated carbon atom. For compounds **2** and **3**, the characteristic chemical shifts of the trifluoromethyl group appeared at δ 84.5–85.0 and 86.0 ppm, respectively (Table S2 in Supplementary Materials).

At the next stage of our work, we studied the cyclization of dibromo derivatives **3a**,**g** in the presence of bases. The use of *t*-BuOK in THF or pyridine, DIPEA, DBU, NaHCO₃ in various solvents (acetone, ethanol, DMSO) at room temperature did not allow us to obtain 4-pyrone **5a** in an acceptable yield. The most favorable conditions turned out to be stirring with a 2.5-fold excess of triethylamine in acetone for three days (Scheme 5). In addition, the isolation of the product, in this case, does not require chromatography, and pyrones

Et₃N Br acetone CF₃ 2HBr 3a,g 5a,g Br –HBr Е –HBr Е Br 1.4-A CF₃ 0 Β̈́r В R = H (a, 51%), 4-MeO (g, 54%)

Br

Α

5a,**g** precipitated in pure form upon dilution with water in 51–54% yields. This approach can be scaled up to 5 g of enedione **2a**, and the yield of pyrone **5a** was 36% in two stages.

Scheme 5. Cyclization of dibromo derivatives 3 to pyrones 5.

The cyclization mechanism of compounds **3** includes the formation of dihydropyran intermediate **B** via two possible pathways. The first path comprises the elimination of hydrogen bromide (E) and the production of bromoenone **A**, which then undergoes an intramolecular Michael reaction $(1,4-A_N)$. The second possibility is the direct intramolecular nucleophilic substitution of bromine (S_N). As mentioned above, the cyclic pyranic form **B** was observed in the bromination reaction mixtures (Table 2), whereas bromoenones **A** were detected by NMR spectroscopy on the treatment of the dibromo derivatives **3** with pyridine at room temperature. The easy formation of 2-bromoenones from 2,3-dibromoketones is also well presented in the literature [42]. Thus, it can be assumed that the first path is more preferable in basic conditions. Intermediate **A'** was isolated in pure form with the use of column chromatography (56% yield) from enedione **2i** via bromination (1 equiv.) and subsequent monodehydrobromination by DIPEA at room temperature.

Tribromo derivatives **4** undergo cyclization under the action of triethylamine in acetone at room temperature much slower, furthermore, the high basicity of the medium could provide a possibility of side reactions associated with detrifluoroacetylation [41]. Therefore, dehydrohalogenation of **4** was carried out by refluxing for 10 h in pyridine as a solvent and a weaker base (Scheme 6). The cyclization of compound **4c** gave pyrone **6c** in 36% yield. These results demonstrate that the cyclization step determines mainly total output of the pyrones. Moreover, the difference in reaction rates of cyclization of tribromo derivatives **4** and dibromo derivatives **3** allowed the isolation of pyrones **5** in the presence of Et₃N in acetone selectively, even when the reaction mixtures of the brominated intermediates were used.



Scheme 6. Cyclization of tribromo derivative 4c to pyrone 6c.

With the optimized conditions of the bromination and cyclization of intermediate bromo derivatives in hand, we decided to develop a simple *one-pot* two-step preparative method for the synthesis of 4-pyrones **5** and **6** based on oxidative cyclization of enediones **2**. Considering that the reaction mixtures of bromination contain various bromine-bearing forms (cyclic and acyclic), the overall efficiency and convenience of this two-step process without intermediate purification can improve (Scheme 7, Table 3).



Scheme 7. One-pot preparation of pyrones 5 and 6 from enediones 2.

For the preparation of 4-pyrones 5 in the *one-pot* approach, enediones 2 were treated with 1 equiv. of bromine in benzene (Method A) for compounds bearing electron-donating substituents (F, Me, MeO) and in CH_2Cl_2 (Method B) for compounds bearing weak electron-withdrawing substituents (Cl, Br) or H at the C-4 position. After bromination, the solvent was evaporated, and the cyclization was carried out using Et_3N (2.5 equiv.) in acetone, as a result, pyrones 5 were obtained in 28–69% yields.

The preparation of 3-bromo-4-pyrones **6** with a *one-pot* method was possible only for substrates bearing weak electron-donating (H, 4-Me, 4-F) and electron-withdrawing groups (4-Cl, 3-NO₂) in the benzene ring since aromatic bromination was unavoidable with an excess of bromine in case of highly activated aryl substituents. At the first stage, enedione **2** was treated with 2.5 equiv. of bromine in CH₂Cl₂ and subsequent heating at 100 °C in pyridine for 10 h led to the formation of pyrones **6** in 4–42% yields (Method C).

Enedione	Ar	Pyrone	Method	Yield, %
2a	Ph	5a	В	48
2b	$4-FC_6H_4$	5b	А	69
2c	$4-ClC_6H_4$	5c	В	62
2d	$4-BrC_6H_4$	5d	В	65
2f	$4-MeC_6H_4$	5f	В	28
2g	$4 - MeOC_6H_4$	5g	А	65
2i	$2-C_4H_3S$	5i	А	62
2a	Ph	6a	С	23
2b	$4-FC_6H_4$	6b	С	28
2c	$4-ClC_6H_4$	6c	С	34
2e	$3-O_2NC_6H_4$	6e	С	4
2f	$4-MeC_6H_4$	6f	С	42

Table 3. The scope of 4-pyrone synthesis via the *one-pot* oxidative cyclization of enediones 2.

Method A: The mixture of enedione **2** (1.0 mmol) with bromine (1.0 mmol) in C_6H_6 was stirred at room temperature. Cyclization was carried out in the presence of Et₃N (2.5 equiv.) in acetone. Method B: The mixture of enedione **2** (1.0 mmol) with bromine (1.0 mmol) was stirred in CH₂Cl₂ at room temperature. Cyclization was carried out in the presence of Et₃N in acetone. Method C: The mixture of enedione **2** (1.0 mmol) with bromine (2.5 mmol) in CH₂Cl₂ was stirred at room temperature. Cyclization was carried in pyridine at 100 °C for 10 h.

This *one-pot* approach was also applied for the preparation of phenyl-4-pyrones bearing various polyfluoroalkyl substituent. No significant difference in reactivity was observed depending on fluorine content or chain length of R^F-moiety, and the cyclization of enediones **2j**–**l** in the presence of 1 equiv. of bromine (Method B) gave 4-pyrones **5j**–**l** in 40–70% yields (Scheme 8). The use of Method C led to 3-bromopyrones **6j**–**l** in 24–33% yields.



Scheme 8. Synthesis of 2-aryl-6-polyfluoroalkyl-4-pyrones 6j-1.

The structure of 4-pyrones **5** and **6** was established on the basis of elemental analysis data, HRMS and NMR spectra. In the ¹H NMR spectra of compounds **5** in CDCl₃, characteristic doublets of H-3 and H-5 protons of the pyrone ring were observed at δ 6.63–6.88 ppm with a coupling constant of 1.8–2.2 Hz. In the case of pyrones **6**, the signal of the H-5 proton of the pyrone ring appeared as a singlet at δ 6.88–7.04 ppm (CDCl₃).

The next step was to study the chemical properties of 2-aryl-6-(trifluoromethyl)-4pyrones with N-nucleophiles to obtain azaheterocycles (Scheme 9). The reaction of pyrone **5a** with ammonia in ethanol in an autoclave at 120 °C for 10 h led to the formation of pyridone **7** in 70% yield. The ring-opening transformation of pyrone **5a** with sodium azide [43] in DMSO afforded triazole **8** in 55% yield. Phenylhydrazine reacted with pyrone **5a** regioselectively attacking with the amino group at the C-2 and C-4 positions to give pyrazole **9**. The structure of pyrazole **9** was assigned based on NMR spectra according to the literature data [16,34].



Scheme 9. Reaction of pyrone 5a with N-nucleophiles for the synthesis of fluorinated azaheterocycles.

Thus, a convenient and general method for the synthesis of 2-aryl-6-polyfluoroalkyl-4-pyrones and their bromo derivatives has been developed based on *one-pot* oxidative cyclization of fluorinated enediones. The selectivity of monobromination of 6-aryl-1,1,1-trifluorohex-5-ene-2,4-diones is connected with the predominant electrophilic attack on the double bond and strongly depends on the solvent used and the nature of the substituent in the aromatic ring, which determines the scope of obtained fluorinated 2-aryl-4-pyrones. 6-Aryl-1,1,1-trifluorohex-5-ene-2,4-diones bearing electron-withdrawing and weak electron-donating substituents in the aromatic ring react with an excess of bromine leading to tribromo derivatives as a result of bromination of the double bond and the diketone moiety. Di- and tribromo derivatives in a basic medium selectively undergo cyclization to form 4-pyrones. The resulting 4-pyrones have proven to be useful building blocks and have been utilized to synthesize CF_3 -bearing heterocycles, which are of further interest in terms of potential biological activity.

3. Materials and Methods

NMR spectra were recorded on Bruker DRX-400 (¹H: 400 MHz, ¹³C: 100 MHz, ¹⁹F: 376.5 MHz) and Bruker Avance III-500 (¹H: 500 MHz, ¹³C: 126 MHz, ¹⁹F: 471 MHz) spectrometers in DMSO- d_6 and CDCl₃. The chemical shifts (δ) are reported in ppm relative to the internal standard TMS (¹H NMR), C₆F₆ (¹⁹F NMR), and residual signals of the solvents (¹³C NMR). IR spectra were recorded on a Shimadzu IRSpirit-T spectrometer using an attenuated total reflectance (ATR) unit (FTIR mode, ZnSe crystal), the absorbance maxima (ν) are reported in cm⁻¹. Elemental analyses were performed on an automatic analyzer PerkinElmer PE 2400. Melting points were determined using a Stuart SMP40 melting point apparatus. Column chromatography was performed on silica gel (Merck 60, 70–230 mesh). All solvents that were used were dried and distilled by standard procedures. Arylideneacetones **1** have been synthesized according to the procedure, previously described in the literature [44].

3.1. Synthesis of Enediones 2a–1

General Procedure. A suspension of NaH (60% by weight in mineral oil) (240 mg, 6.0 mmol) in dry Et_2O (5 mL) was cooled on an ice bath, then CF_3CO_2Et (0.86 g, 6.0 mmol) and a solution of arylideneacetone 1 (4.0 mmol) in dry Et_2O (3 mL) were successively added under stirring. The reaction mixture was warmed to room temperature and stirred for 20 h. Then 1M aqueous HCl (10 mL) was added, and the organic phase was separated (if the precipitate of diketonate formed, it was filtered and treated with 1M aqueous HCl (10 mL)). The aqueous phase was extracted with AcOEt (5 mL). The combined organics were washed with H₂O and dried over anhydrous Na₂SO₄, the solvents evaporated, and

the residue recrystallized from hexane with decantation of hot solution from insoluble tarry by-products.

General procedure (with LiH) [38]. A solution of arylideneacetone 1 (4.0 mmol) in dry C_6H_6 (1 mL) and CF_3CO_2Et (0.86 g, 6.0 mmol) were successively added to a suspension of LiH (48 mg, 6.0 mmol) in dry C_6H_6 (4 mL) under stirring. The reaction mixture was warmed until the reaction started and then was stirred at room temperature for 20 h. After that, the reaction mixture was poured into a mixture of ice (4 g) and H_2SO_4 (1 mL), extracted with chloroform (5 mL), and dried over MgSO₄. The solvents were evaporated, and the residue recrystallized from hexane with decantation of hot solution from insoluble tarry by-products.

(*E*)-1,1,1-*Trifluoro-6-phenylhex-5-ene-2,4-dione* (**2a**). Yield 0.73 g (75%), colorless needles, mp 56–58 °C (lit. mp 58 °C [40], 61–61.5 °C [38]).¹H NMR (400 MHz, CDCl₃) enol form: δ 6.04 (1H, s, 3-CH); 6.58 (1H, d, *J* = 15.9 Hz, 5-CH); 7.37–7.57 (3H, m, H Ph); 7.53–7.61 (2H, m, H-2, H-6 Ph); 7.77 (1H, d, *J* = 15.9 Hz, 6-CH); 14.22 (1H, s, OH). The analytical data are in consistence with the literature [38,40].

(*E*)-1,1,1-*Trifluoro-6-(4-fluorophenyl)hex-5-ene-2,4-dione* (**2b**). Yield 0.67 g (64%), yellow prisms, mp 83–84 °C. IR (ATR) v 1637, 1578, 1509, 1444, 1414. ¹H NMR (500 MHz, CDCl₃) enol form: δ 6.02 (1H, s, 3-CH); 6.50 (1H, d, *J* = 15.8 Hz, 5-CH); 7.12 (2H, t, *J* = 8.6 Hz, *J*_{HF} = 8.6 Hz, H-3, H-5 Ar); 7.57 (2H, dd, *J* = 8.7 Hz, *J* = 5.3 Hz, H-2, H-6 Ar); 7.73 (1H, d, *J* = 15.8 Hz, 6-CH); 14.24 (1H, s, OH). ¹⁹F NMR (376 MHz, CDCl₃) δ 53.9 (tt, *J*_{HF} = 8.4 Hz, *J*_{HF} = 5.4 Hz, F); 84.7 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 95.6 (q, ³*J*_{CF} = 1.4 Hz, C-3); 116.4 (d, ²*J*_{CF} = 22.0 Hz, C-3, C-5 Ar); 116.7 (q, ¹*J*_{CF} = 286.6 Hz, CF₃); 120.8 (d, ⁶*J*_{CF} = 2.4 Hz, C-5); 130.4 (s, C-1 Ar); 130.5 (d, ⁴*J*_{CF} = 8.8 Hz, C-2, C-6 Ar); 142.3 (C-6); 164.3 (d, ¹*J*_{CF} = 253.2 Hz, C-4 Ar); 180.5 (q, ²*J*_{CF} = 36.1 Hz, C-2); 180.8 (C-4). HRMS (ESI) *m*/z [M + H]⁺. Calcd for C₁₂H₉F₄O₂: 261.0539. Found: 261.0533.

(*E*)-6-(4-*Chlorophenyl*)-1,1,1-*trifluorohex*-5-*ene*-2,4-*dione* (**2c**). Yield 0.66 g (60%), yellow needles, mp 92–93 °C. IR (ATR) ν 3072, 3035, 1632, 1610, 1573, 1561, 1491, 1454, 1410. ¹H NMR (500 MHz, CDCl₃) enol form: δ 6.03 (1H, s, 3-CH); 6.54 (1H, d, *J* = 15.8 Hz, 5-CH); 7.40 (2H, d, *J* = 8.5 Hz, H Ar); 7.50 (2H, d, *J* = 8.5 Hz, H Ar); 7.71 (1H, d, *J* = 15.8 Hz, 6-CH); 14.17 (1H, s, OH). ¹⁹F NMR (471 MHz, CDCl₃) δ 84.6 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 95.80 (q, ³*J*_{CF} = 1.4 Hz, C-3); 116.63 (q, ¹*J*_{CF} = 285.6 Hz, CF₃); 121.5 (s, C-5); 129.4 (s, 2H); 129.6 (s, 2H); 132.7 (s, C Ar); 137.1 (s, C Ar); 142.1 (s, C-6); 180.4 (s, C-4); 180.8 (q, ²*J*_{CF} = 36.1 Hz, C-2). Anal. Calcd for C₁₂H₈ClF₃O₂: C 52.10; H 2.91. Found: C 51.93; H 2.94%.

(*E*)-6-(4-*Bromophenyl*)-1,1,1-*trifluorohex-5-ene-2,4-dione* (**2d**). Yield 1.18 g (92%), white crystals, mp 86–87 °C. IR (ATR) v 1632, 1609, 1582, 1487, 1454, 1406. ¹H NMR (400 MHz, CDCl₃) enol form: δ 6.03 (1H, s, 3-CH); 6.56 (1H, d, ³*J* = 15.9 Hz, 5-CH); 7.43 (2H, d, ³*J* = 8.4 Hz, H Ar); 7.56 (2H, d, ³*J* = 8.4 Hz, H Ar); 7.69 (1H, d, ³*J* = 15.9 Hz, 6-CH); 14.15 (1H, s, OH). ¹⁹F NMR (376 MHz, CDCl₃) δ 84.7 (s, CF₃). ¹³C NMR (101 MHz, CDCl₃) δ 95.8 (unresolved q, C-3); 116.7 (q, ¹*J*_{CF} = 285.5 Hz, CF₃); 121.6 (C-5); 125.5 (C Ar); 129.8 (2C Ar); 132.4 (2C Ar); 133.1 (C Ar); 142.1 (C-6); 180.4 (C-4); 180.8 (q, ²*J*_{CF} = 36.2 Hz, C-2). Anal. Calcd for C₁₂H₈BrF₃O₂: C 44.89; H 2.51. Found: C 45.03; H 2.57%.

(*E*)-1,1,1-*Trifluoro-6-(3-nitrophenyl)hex-5-ene-2,4-dione* (**2e**). Yield 0.59 g (51%), white scales, mp 118–119 °C. IR (ATR) ν 1644, 1610, 1577, 1523, 1477, 1429. ¹H NMR (400 MHz, CDCl₃) enol form: δ 6.10 (1H, s, 3-CH); 6.70 (1H, d, ³*J* = 15.9 Hz, 5-CH); 7.63 (1H, t, ³*J* = 8.0 Hz, H-5 Ar); 7.79 (1H, d, ³*J* = 15.9 Hz, 6-CH); 7.86 (1H, dt, ³*J* = 7.7 Hz, ⁴*J* = 1.0 Hz, H-6 Ar); 8.27 (1H, ddd, ³*J* = 8.5 Hz, ⁴*J* = 2.1 Hz, ⁴*J* = 0.8 Hz, H-4 Ar); 8.44 (1H, t, ⁴*J* = 1.8 Hz, H-2 Ar); 13.96 (1H, s, OH). ¹⁹F NMR (376 MHz, CDCl₃) δ 84.5 (s, CF₃). HRMS (ESI) *m*/*z* [M – H]⁻. Calcd for C₁₂H₇F₃NO₄: 286.0327. Found: 286.0331.

(*E*)-1,1,1-*Trifluoro-6-(p-tolyl)hex-5-ene-2,4-dione* (**2f**). Yield 0.67 g (65%), yellow needles, mp 61–62 °C. IR (ATR) ν 3031, 2956, 2926, 2360, 1652, 1594, 1575, 1516, 1447, 1416. ¹H NMR (400 MHz, CDCl₃) enol form: δ 2.40 (3H, s, Me); 6.01 (1H, s, 3-CH); 6.53 (1H, d, *J* = 15.8 Hz, 5-CH); 7.23 (2H, d, *J* = 8.0 Hz, H-3, H-5 Ar); 7.47 (2H, d, *J* = 8.1 Hz, H-2, H-6 Ar); 7.75 (1H,

d, J = 15.8 Hz, 6-CH); 14.30 (1H, s, OH). ¹⁹F NMR (376 MHz, CDCl₃) δ 84.7 (s, CF₃). ¹³C NMR (101 MHz, CDCl₃) δ 21.6 (CH₃); 95.4 (q, ³*J*_{CF} = 1.5 Hz, C-3); 116.8 (q, ¹*J*_{CF} = 285.3 Hz, CF₃); 120.0 (C-5); 128.6 (2C Ar); 129.9 (2C Ar); 131.5 (C Ar); 141.9 (C Ar); 143.90 (C-6); 180.1 (q, ²*J*_{CF} = 36.0 Hz, C-2); 181.5 (C-4). Anal. Calcd for C₁₃H₁₁F₃O₂: C 60.94; H 4.33. Found: C 60.96; H 4.47%. The analytical data are in consistence with the literature [41].

(*E*)-1,1,1-*Trifluoro-6-(4-methoxyphenyl)hex-5-ene-2,4-dione* (**2g**). Yield 0.88 g (81%), yellow needles, mp 100–101 °C (lit. mp 98 °C [40]). IR (ATR) v 1633, 1568, 1511, 1453, 1441, 1420. ¹H NMR (500 MHz, CDCl₃) enol form: δ 3.86 (3H, s, OMe); 6.00 (1H, s, 3-CH); 6.45 (1H, d, ³*J* = 15.8 Hz, 5-CH); 6.94 (2H, d, ³*J* = 8.8 Hz, H-3, H-5 Ar); 7.53 (2H, d, ³*J* = 8.4 Hz, H-2, H-6 Ar); 7.74 (1H, d, ³*J* = 15.8 Hz, 6-CH); 14.45 (1H, s, OH). ¹⁹F NMR (471 MHz, CDCl₃) δ 84.8 (s, CF₃). ¹³C NMR (101 MHz, CDCl₃) δ 55.5 (OMe); 95.2 (q, ²*J*_{CF} = 1.2 Hz, C-3); 114.7 (2C Ar); 116.9 (q, ¹*J*_{CF} = 285.1 Hz, CF₃); 118.6 (C-5); 126.9 (C Ar); 130.5 (2C Ar); 143.7 (C-6); 162.2 (C Ar); 179.7 (q, ²*J*_{CF} = 35.9 Hz, C-2); 181.9 (C-4). Anal. Calcd for C₁₃H₁₁F₃O₃: C 57.36; H 4.07. Found: C 57.38; H 4.20%. The analytical data are in consistence with the literature [40].

(*E*)-6-(4-(*Dimethylamino*)*phenyl*)-1,1,1-*trifluorohex*-5-*ene*-2,4-*dione* (**2h**). Yield 0.76 g (67%), magenta needles, mp 79–80 °C (lit. mp 78–79 °C [39]). IR (ATR) v 2900, 1556, 1519, 1453, 1430, 1360, 1328. ¹H NMR (500 MHz, CDCl₃) enol form: δ 3.07 (6H, s, NMe₂); 5.95 (1H, s, 3-CH); 6.35 (1H, d, ³*J* = 15.6 Hz, 5-CH); 6.68 (2H, d, ³*J* = 8.9 Hz, H-3, H-5 Ar); 7.47 (2H, d, ³*J* = 8.9 Hz, H-2, H-6 Ar); 7.74 (1H, d, ³*J* = 15.6 Hz, 6-CH); 14.69 (1H, s, OH). ¹⁹F NMR (471 MHz, CDCl₃) δ 85.0 (s, CF₃). Anal. Calcd for C₁₄H₁₄F₃NO₂: C 58.95; H 4.95; N 4.91. Found: C 58.92; H 4.94; N 4.79%. The analytical data are in consistence with the literature [39].

(*E*)-1,1,1-*Trifluoro-6-(thiophen-2-yl)hex-5-ene-2,4-dione* (**2i**). Yield 0.83 g (84%), yellow rectangular prisms, mp 94–95 °C. IR (ATR) v 1577, 1503, 1437, 1416. ¹H NMR (400 MHz, CDCl₃) enol form: δ 5.99 (1H, s, 3-CH); 6.36 (1H, d, ³*J* = 15.5 Hz, 5-CH); 7.11 (1H, dd, ³*J* = 4.9 Hz, ³*J* = 3.8 Hz, H-4 Th); 7.35 (1H, d, ³*J* = 3.5 Hz, H-3 Th); 7.48 (1H, d, ³*J* = 5.0 Hz, H-5 Th); 7.88 (1H, d, ³*J* = 15.5 Hz, 6-CH); 14.28 (1H, s, OH). ¹⁹F NMR (376 MHz, CDCl₃) δ 84.8 (s, CF₃). ¹³C NMR (101 MHz, CDCl₃) δ 95.5 (unresolved q, C-3); 116.8 (q, ¹*J*_{CF} = 285.3 Hz, CF₃); 119.8 (C-5); 128.6; 130.2; 132.4; 136.2; 139.8; 180.1 (q, ²*J*_{CF} = 36.0 Hz, C-2); 180.8 (C-4). Anal. Calcd for C₁₀H₇F₃O₂S: C 48.39; H 2.84. Found: C 48.36; H 2.75%.

(E)-1,1-Difluoro-6-phenylhex-5-ene-2,4-dione (**2j**). Yield 0.39 g (43%), yellow crystals, mp 85–87 °C. IR (ATR) v 3030, 1647, 1495, 1341, 1180, 1105, 867, 757. ¹H NMR (500 MHz, CDCl₃) enol form: δ 5.91 (1H, t, ²*J*_{HF} = 54.3 Hz, CF₂H); 6.04 (1H, s, 3-CH); 6.58 (1H, d, *J* = 15.9 Hz, 5-CH); 7.39–7.44 (3H, m, H Ph); 7.51–7.62 (2H, m, H-2, H-6 Ph); 7.72 (1H, d, *J* = 15.9 Hz, 6-CH); 14.58 (1H, s, OH). ¹⁹F NMR (471 MHz, CDCl₃) δ 35.0 (dd, ²*J*_{HF} = 54.4 Hz, ⁴*J*_{HF} = 0.5 Hz, CF₂H). ¹³C NMR (126 MHz, CDCl₃) δ 96.0 (t, ³*J*_{CF} = 1.9 Hz, C-4); 109.6 (t, ¹*J*_{CF} = 249.0 Hz, CF₂H); 121.8 (C-6); 128.4 (2C Ph); 129.1 (2C Ph); 130.8 (C Ph); 134.4 (C Ph); 142.7 (C-7); 181.0 (C-5); 186.5 (t, ²*J*_{CF} = 25.7 Hz, C-3). Anal. Calcd for C₁₂H₁₀F₂O₂: C 64.29; H 4.50. Found: C 64.69; H 4.35.

(*E*)-6,6,7,7-*Tetrafluoro-1-phenylhept-1-ene-3,5-dione* (**2k**). Yield 0.47 g (43%), yellow liquid. IR (ATR) v 3028, 1633, 1580, 1449, 1244, 1110, 700. ¹H NMR (400 MHz, CDCl₃) enol form: δ 6.10 (tt, ²*J*_{HF} = 52.9 Hz, ³*J*_{HF} = 5.1 Hz, CF₂H); 6.13 (1H, s, 4-CH); 6.58 (1H, d, *J* = 15.9 Hz, 6-CH); 7.40–7.45 (3H, m, H Ph); 7.53–7.61 (2H, m, H-2, H-6 Ph); 7.77 (1H, d, *J* = 15.9 Hz, 7-CH); 14.45 (1H, s, OH). ¹⁹F NMR (376 MHz, CDCl₃) δ 23.4 (dt, ²*J*_{HF} = 52.9 Hz, ³*J*_{FF} = 6.9 Hz, CF₂H); 35.8 (tdd, ³*J*_{FF} = 6.9 Hz, ³*J*_{HF} = 5.1 Hz, ⁴*J*_{HF} = 0.8 Hz, CF₂). ¹³C NMR (126 MHz, CDCl₃) δ 96.8 (unresolved t, C-4); 109.1 (tt, ¹*J*_{CF} = 251.2 Hz, ²*J*_{CF} = 34.1 Hz, CF₂H); 109.5 (tt, ¹*J*_{CF} = 258.5 Hz, ²*J*_{CF} = 27.8 Hz, CF₂); 121.3 (C-6); 128.4 (2C Ph); 129.1 (2C Ph); 131.0 (C Ph); 134.3 (C Ph); 143.6 (C-7); 180.1 (q, ²*J*_{CF} = 26.7 Hz, C-3); 180.9 (C-5). HRMS (ESI) *m/z* [M + H]⁺. Calcd for C₁₃H₁₁F₄O₂: 275.0695. Found: 275.0694.

(*E*)-6,6,7,7,8,8,9,9-Octafluoro-1-phenylnon-1-ene-3,5-dione (**2l**). Yield 0.76 g (51%), yellow liquid. IR (ATR) ν 2929, 1633, 1580, 1450, 1172, 1034, 972, 787. ¹H NMR (500 MHz, CDCl₃) δ enol form (88%): 6.08 (1H, s, 4-CH); 6.12 (1H, tt, ${}^{2}J_{\rm HF}$ = 52.0 Hz, ${}^{3}J_{\rm HF}$ = 5.5 Hz, CF₂H); 6.58 (1H, d, *J* = 15.8 Hz, 2-CH); 7.39–7.47 (3H, m, H Ph); 7.54–7.61 (2H, m, H-2, H-6 Ph); 7.79 (1H, d, *J* = 15.8 Hz, 1-CH); 14.33 (1H, s, OH); keto form (12%): 2.77 (2H, s, CH₂); 6.08 (1H, tt, ${}^{2}J_{\rm HF}$ = 52.0 Hz, ${}^{3}J_{\rm HF}$ = 5.5 Hz, CF₂H); 6.46 (1H, d, *J* = 15.9 Hz, 2-CH); 7.39–7.47 (3H, m, H Ph); 7.54–7.61 (2H, m, H-2, H-6 Ph); 7.81 (1H, d, *J* = 15.9 Hz, 2-CH); 7.39–7.47 (3H, m, H Ph); 7.54–7.61 (2H, m, H-2, H-6 Ph); 7.81 (1H, d, *J* = 15.9 Hz, 1-CH). ¹⁹F NMR (471 MHz, CDCl₃) δ enol form (88%): 24.4 (dm, ${}^{2}J_{\rm HF}$ = 51.9 Hz, CF₂H); 32.0 –32.1 (m, 8-CF₂); 37.0 (t, ${}^{3}J_{\rm FF}$ = 8.2 Hz, 7-CF₂); 40.5 (t, ${}^{3}J_{\rm FF}$ = 9.9 Hz, 6-CF₂); keto form (12%): 24.4 (dm, ${}^{2}J_{\rm HF}$ = 51.9 Hz, CF₂H); 31.9–32.0 (m, 8-CF₂); 36.9 (t, ${}^{3}J_{\rm FF}$ = 8.2 Hz, 7-CF₂); 42.3 (t, ${}^{3}J_{\rm FF}$ = 9.6 Hz, 6-CF₂). ¹³C NMR (126 MHz, CDCl₃) δ 97.2 (unresolved m, C-6); 107.6 (tt, ${}^{1}J_{\rm CF}$ = 254.7 Hz, ${}^{2}J_{\rm CF}$ = 30.9 Hz, CF₂H); 107.7–113.5 (m, 3CF₂); 121.0 (C-8); 128.5 (2C Ph); 129.1 (2C Ph); 131.2 (C Ph); 134.2 (C Ph); 144.0 (C-9); 180.5 (C-7); 182.5 (t, ${}^{2}J_{\rm CF}$ = 26.7 Hz, C-5). HRMS (ESI) *m/z* [M + H]⁺. Calcd for C₁₅H₁₁F₈O₂: 375.0631. Found: 375.0627.

3.2. Synthesis of Compounds 3a,g

General procedure. A solution of Br_2 (3.20 g, 0.020 mol) in glacial AcOH (5.7 mL) was added dropwise to enedione 2 (0.020 mol) in glacial AcOH (18 mL) cooled by a water bath. After that, the reaction mixture was stirred for 1 h at room temperature. The resulting solution was diluted by water (30 mL). The precipitate that formed was filtered. If it is needed, the pure product can be obtained by recrystallization from heptane.

(5*S*,6*R*)-5,6-*Dibromo*-1,1,1-*trifluoro*-6-*phenylhexane*-2,4-*dione* (**3a**). Yield 5.71 g (71%), beige powder, mp 119–120 °C. IR (ATR) v 1665, 1629, 1604, 1497, 1458, 1434. ¹H NMR (400 MHz, DMSO-*d*₆) enol form: δ 5.56 (1H, d, ³*J* = 11.7 Hz, CHBr); 6.08 (1H, d, ³*J* = 11.7 Hz, CHBr); 6.30 (1H, s, 3-CH); 7.29–7.46 (3H, m, H Ph); 7.49–7.54 (2H, m, H-2, H-6 Ph). ¹H NMR (400 MHz, CDCl₃) δ 4.96 (1H, d, ³*J* = 11.6 Hz, CHBr); 5.39 (1H, d, ³*J* = 11.6 Hz, CHBr); 6.24 (1H, s, 3-CH); 7.38–7.50 (5H, m, H Ph). ¹⁹F NMR (471 MHz, CDCl₃) δ 86.0 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 48.8; 51.2; 96.5; 117.1 (q, *J* = 280.4 Hz, CF₃); 128.0; 129.0; 129.6; 137.4; 171.9 (q, *J* = 37.2 Hz, C-2); 190.6. HRMS (ESI) *m*/*z* [M – H][–]. Calcd for C₁₂H₈Br₂F₃O₂: 398.8843. Found: 398.8835.

(5*S*,6*R*)-5,6-*Dibromo*-1,1,1-*trifluoro*-6-(4-*methoxyphenyl*)*hexane*-2,4-*dione* (**3g**). Yield 2.42 g (28%), yellow powder, mp 124–125 °C. IR (ATR) ν 1665, 1607, 1514, 1462, 1443. ¹H NMR (500 MHz, CDCl₃) enol form: δ 3.84 (3H, s, OMe); 4.93 (1H, d, ³*J* = 11.6 Hz, CHBr); 5.37 (1H, d, ³*J* = 11.6 Hz, CHBr); 6.21 (1H, s, 3-CH); 6.92 (2H, d, ³*J* = 8.6 Hz, H-3, H-5 Ar); 7.35 (2H, d, ³*J* = 8.6 Hz, H-2, H-6 Ar); 13.50 (1H, s, OH). ¹⁹F NMR (376 MHz, CDCl₃) δ 86.0 (s, CF₃). Anal. Calcd for C₁₃H₁₁Br₂F₃O₃: C 36.14; H 2.57. Found: C 36.48; H 2.73%.

3.3. Synthesis of Compound 4c

A solution of Br₂ (400 mg, 2.5 mmol) in CH₂Cl₂ (2 mL) was added to enedione **2c** (277 mg, 1 mmol) in CH₂Cl₂ (8 mL) under cooling on an ice-bath. The reaction mixture was left at room temperature for 15 h, and then the solvent was evaporated without heating. The residue is a mixture of diastereoisomeres (dr = 80:20), which was recrystallized from hexane to obtain single isomer in pure form for analysis.

(1*R'*,2*S'*)-1,2,4-*Tribromo*-1-(4-chlorophenyl)-6,6,6-trifluoro-5,5-dihydroxyhexan-3-one (**4c**). Yield 0.44 g (82%), white powder, mp 125–128 °C (toluene-hexane). After recrystallization from hexane, mp 154–155 °C (for the major diastereoisomer in pure form). IR (ATR) v 3015, 1714, 1597, 1493, 1295, 1207, 990, 830, 715. ¹H NMR (500 MHz, CDCl₃) δ major diastereomer (80%): 4.38 (1H, s, OH); 4.74 (1H, s, OH); 4.95 (1H, s, 4-CHBr); 5.24 (1H, d, ³*J* = 11.3 Hz, 2-CHBr); 5.35 (1H, d, ³*J* = 11.3 Hz, 1-CHBr); 7.32–7.43 (4H, m, H Ar); minor diastereomer (20%): 3.94 (1H, s, OH); 4.58 (1H, s, OH); 4.98 (1H, s, 4-CHBr); 5.19 (1H, d, ³*J* = 11.3 Hz, 2-CHBr); 5.27 (1H, d, ³*J* = 11.3 Hz, 1-CHBr); 7.34–7.41 (4H, m, H Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ major diastereomer: 79.7 (s, CF₃). Anal. Calcd for C₁₂H₉Br₃ClF₃O₃: C 27.02; H 1.70. Found: C 27.32; H 1.79%.

3.4. Synthesis of Compound A'

A solution of dibromide **3i**, which was prepared by reaction of enedione **2i** (248 mg, 1 mmol) with Br_2 (160 mg, 1 mmol) in CH_2Cl_2 (3.4 mL) without additional purification, and DIPEA (323 mg, 2.5 mmol) in CH_2Cl_2 (5 mL) was stirred at room temperature for 15 h. The reaction mixture was then quenched with aqueous HCl (10 mL, 0.5 M), the organic phase was separated, washed with water and brine, dried under Na_2SO_4 , and evaporated. The crude product was purified by column chromatography (CH_2Cl_2).

5-Bromo-1,1,1-trifluoro-6-(thiophen-2-yl)hex-5-ene-2,4-dione (**A'**). Yield 183 mg (56%), dark yellow solid, mp 84–85 °C. IR (ATR) v 1623, 1573, 1413. ¹H NMR (500 MHz, CDCl₃) enol form: δ 6.69 (1H, s, 3-CH); 7.22 (1H, dd, ${}^{3}J$ = 4.9 Hz, ${}^{3}J$ = 3.5 Hz, H-4 Th); 7.65 (1H, d, ${}^{3}J$ = 3.5 Hz, H-3 Th); 7.72 (1H, d, ${}^{3}J$ = 4.9 Hz, H-5 Th); 8.53 (1H, s, 6-CH); 14.77 (1H, s, OH). ¹⁹F NMR (471 MHz, CDCl₃) δ 85.5 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 95.0 (q, ${}^{3}J_{CF}$ = 2.1 Hz, C-4); 112.4; 117.2 (q, ${}^{1}J_{CF}$ = 283.1 Hz, CF₃); 127.6; 133.2; 134.1; 136.9; 137.7; 176.2 (q, ${}^{2}J_{CF}$ = 37.1 Hz, C-2); 182.3 (C-4). HRMS (ESI) *m*/*z* [M + H]⁺. Calcd for C₁₀H₇BrF₃O₂S: 326.9302. Found: 326.9315.

3.5. Synthesis of Pyrones 5

General procedure. A solution of Br₂ (160 mg, 1.0 mmol) in the solvent (1.7 mL) was added to enedione 2 (1 mmol) in the solvent (2.7 mL) under cooling on an ice-bath (C_6H_6 was used for Method A, CH_2Cl_2 – Method B). After that, the reaction mixture was stirred at room temperature for 15 h, and then the solvent was evaporated without heating. Then acetone (4.3 mL) was added to the residue, and the solution was treated with Et₃N (0.253 g, 2.5 mmol) under cooling on an ice-bath. After that, the reaction mixture was stirred at room temperature for 3 days and was diluted with H₂O (15 mL). The precipitate was filtered, washed with water, and recrystallized from hexane.

2-Phenyl-6-(trifluoromethyl)-4H-pyran-4-one (**5a**). Method B. Yield 115 mg (48%), pale-yellow fine crystals, mp 85–86 °C. Procedure from dibromide **3a**: Solutions of dibromide **3a** (2.00 g, 5.0 mmol) in acetone (20 mL) was treated with Et₃N (1.26 g, 12.5 mmol) under cooling on an ice bath. After that, the reaction mixture was stirred at room temperature for 3 days and diluted with H₂O (75 mL). The precipitate was filtered, washed with water, and recrystallized from hexane. Yield 51% (0.60 g), pale-yellow fine crystals, mp 85–86 °C. IR (ATR) v 3068, 1668, 1632, 1605, 1579, 1498, 1451, 1415. ¹H NMR (400 MHz, CDCl₃) δ 6.76 (1H, d, ⁴J = 2.1 Hz, CH); 6.84 (1H, d, ⁴J = 2.1 Hz, CH); 7.50–7.61 (3H, m, H Ph); 7.76–7.80 (m, 2H, H-2, H-6 Ph). ¹⁹F NMR (471 MHz, CDCl₃) δ 90.3 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 112.3; 114.7 (q, ³J_{CF} = 2.3 Hz, C-5); 118.5 (q, ¹J_{CF} = 274.8 Hz, CF₃); 126.0 (2C Ar); 129.3 (2C Ar); 129.9; 132.2; 152.4 (q, ²J_{CF} = 39.6 Hz, C-6); 163.9; 178.0 (CO). Anal. Calcd for C₁₂H₇F₃O₂: C 60.01; H 2.94. Found: C 59.63; H 2.56%.

2-(4-Fluorophenyl)-6-(trifluoromethyl)-4H-pyran-4-one (**5b**). Method A. Yield 0.18 g (69%), beige powder, mp 109–110 °C. IR (ATR) v 3064, 1674, 1637, 1601, 1509, 1291, 1085, 945, 838. ¹H NMR (400 MHz, CDCl₃) δ 6.78 (1H, d, ⁴*J* = 2.1 Hz, CH); 6.82 (1H, d, ⁴*J* = 2.1 Hz, CH); 7.19–7.25 (2H, m, H-3, H-5 Ar); 7.76–7.85 (2H, m, H-2, H-6 Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ 55.8 (tt, ³*J*_{FH} = 8.2 Hz, ⁴*J*_{FH} = 5.1 Hz, F-Ar); 90.3 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 112.1 (d, ⁶*J*_{CF} = 0.8 Hz, C-4); 114.8 (q, ³*J*_{CF} = 2.6 Hz, C-5); 116.7 (d, ²*J*_{CF} = 22.3 Hz, C-3, C-5 Ar); 118.3 (q, ¹*J*_{CF} = 273.5 Hz, CF₃); 126.1 (d, ⁴*J*_{CF} = 3.3 Hz, C-1 Ar); 128.3 (d, ³*J*_{CF} = 9.0 Hz, C-2, C-6 Ar); 152.4 (q, ²*J*_{CF} = 39.4 Hz, C-6); 163.0 (C-2); 164.9 (d, ¹*J*_{CF} = 253.2 Hz, C-4 Ar); 177.9 (CO). Anal. Calcd for C₁₂H₆F₄O₂·0.33H₂O: C 54.57; H 2.54. Found: C 54.31; H 2.57%.

2-(4-Chlorophenyl)-6-(trifluoromethyl)-4H-pyran-4-one (**5c**). Method B. Yield 170 mg (62%), beige crystals, mp 135–137 °C. IR (ATR) v 3061, 1671, 1632, 1605, 1492, 1416, 1407. ¹H NMR (400 MHz, CDCl₃) δ 6.76 (1H, d, ⁴*J* = 2.1 Hz, CH); 6.81 (1H, d, ⁴*J* = 2.1 Hz, CH); 7.51 (2H, d, ³*J* = 8.7 Hz, H Ar); 7.72 (2H, d, ³*J* = 8.7 Hz, H Ar). ¹⁹F NMR (376 MHz, CDCl₃) δ 90.3 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 112.4 (C-3); 114.8 (q, ³*J*_{CF} = 2.6 Hz, C-5); 118.4 (q, ¹*J*_{CF} = 273.7 Hz, CF₃); 127.3 (2C Ar); 128.3 (C Ar); 129.7 (2C Ar); 138.7; 152.4 (q,

 ${}^{2}J_{CF}$ = 39.6 Hz, C-6); 162.8; 177.7 (CO). Anal. Calcd for C₁₂H₆ClF₃O₂: C 52.48; H 2.20. Found: C 52.47; H 2.40%.

2-(4-Bromophenyl)-6-(*trifluoromethyl*)-4H-pyran-4-one (**5d**). Method B. Yield 0.207 mg (65%), colorless powder, mp 161–163 °C. IR (ATR) v 3059, 1668, 1654, 1645, 1627, 1600, 1590, 1488, 1414, 1402. ¹H NMR (500 MHz, CDCl₃) δ 6.76 (1H, d, ⁴*J* = 2.1 Hz, H-3); 6.82 (1H, d, ⁴*J* = 2.1 Hz, H-5); 7.64 (2H, d, ³*J* = 8.8 Hz, H Ar); 7.67 (2H, d, ³*J* = 8.8 Hz, H Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ 90.3 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 112.4 (C-3); 114.9 (q, ³*J*_{CF} = 2.6 Hz, C-5); 118.4 (q, ¹*J*_{CF} = 273.9 Hz, CF₃); 127.1 (C Ar); 127.4 (2C Ar); 128.8 (C Ar); 132.6 (2C Ar); 152.4 (q, ²*J*_{CF} = 39.7 Hz, C-6); 162.9 (C-2); 177.7 (CO). Anal. Calcd for C₁₂H₆BrF₃O₂: C 45.17; H 1.90. Found: C 45.00; H 1.94%.

2-(*p*-*Tolyl*)-6-(*trifluoromethyl*)-4*H*-*pyran*-4-*one* (**5f**). Method B. Yield 71 mg (28%), colorless needles, 105–107 °C. IR (ATR) v 1645, 1632, 1608, 1594, 1569, 1511, 1447. ¹H NMR (500 MHz, CDCl₃) δ 2.44 (3H, s, Me); 6.74 (1H, d, *J* = 2.1 Hz, H-5); 6.80 (1H, d, *J* = 2.1 Hz, H-3); 7.32 (2H, d, *J* = 8.1 Hz, H-3, H-5 Ar); 7.67 (2H, d, *J* = 8.1 Hz, H-2, H-6 Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ 90.3 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 21.5 (CH₃); 111.6 (C-3); 114.6 (q, ³*J*_{CF} = 2.5 Hz, C-5); 118.5 (q, ¹*J*_{CF} = 273.8 Hz, CF₃); 125.9 (2C Ar); 127.0 (C Ar); 130.0 (2C Ar); 143.1(C Ar); 152.3 (q, ²*J*_{CF} = 39.5 Hz, C-6); 164.1 (C-2); 178.0 (CO). HRMS (ESI) *m*/*z* [M + H]⁺. Calcd for C₁₃H₁₀F₃O₂: 255.0633. Found: 255.0625.

2-(4-*Methoxyphenyl*)-6-(*trifluoromethyl*)-4*H*-*pyran*-4-one (**5g**). Method A. Yield 176 mg (65%), yellow crystals, mp 106–107 °C. IR (ATR) ν 3019, 1685, 1598, 1522, 1489, 1432. ¹H NMR (500 MHz, CDCl₃) δ 3.89 (3H, s, Me); 6.73 (1H, d, ⁴*J* = 2.1 Hz, CH); 6.75 (1H, d, ⁴*J* = 2.1 Hz, CH); 7.02 (2H, d, ³*J* = 8.9 Hz, H-3, H-5 Ar); 7.73 (2H, d, ³*J* = 8.9 Hz, H-2, H-6 Ar). ¹⁹F NMR (376 MHz, CDCl₃) δ 90.3 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 55.5 (CH₃); 110.7 (C-3); 114.6 (q, ³*J*_{CF} = 2.5 Hz, C-5); 114.7 (2C Ar); 118.6 (q, ¹*J*_{CF} = 273.6 Hz, CF₃); 122.1 (C Ar); 127.8 (2C Ar); 152.1 (q, ²*J*_{CF} = 39.4 Hz, C-6); 162.9; 164.0; 178.0 (CO). Anal. Calcd for C₁₃H₉F₃O₃: C 57.79; H 3.36. Found: C 57.39; H 3.39%.

2-(*Thiophen-2-yl*)-6-(*trifluoromethyl*)-4H-pyran-4-one (**5i**). Method A. Yield 153 mg (62%), yellow crystals, mp 87–88 °C. IR (ATR) ν 3042, 1668, 1652, 1630, 1594, 1427, 1408. ¹H NMR (400 MHz, CDCl₃) δ 6.68 (1H, d, *J* = 2.1 Hz, H-5); 6.71 (1H, d, *J* = 2.1 Hz, H-3); 7.19 (1H, dd, ³*J* = 4.9 Hz, ³*J* = 3.9 Hz, H-4 Th); 7.60 (1H, d, ³*J* = 4.9 Hz, H-5 Th); 7.65 (1H, d, ³*J* = 3.9 Hz, H-3 Th). ¹⁹F NMR (376 MHz, CDCl₃) δ 90.3 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 110.7 (C-3); 114.8 (q, ³*J*_{CF} = 2.4 Hz, C-5); 118.4 (q, ¹*J*_{CF} = 274.2 Hz, CF₃); 128.7 (C Ar); 129.1 (C Ar); 130.9 (C Ar); 132.9 (C Ar); 151.9 (q, ²*J*_{CF} = 39.7 Hz, C-6); 159.5; 177.4 (CO). HRMS (ESI) *m*/*z* [M + H]⁺. Calcd for C₁₀H₆F₃O₂S: 247.0041. Found: 247.0031.

2-(*Difluoromethyl*)-6-*phenyl*-4H-*pyran*-4-*one* (**5***j*). Yield 40% (89 mg), yellow powder, mp 135–136 °C. IR (ATR) v 1665, 1616, 1596, 1497, 1358, 1177, 1108, 1055, 925. ¹H NMR (500 MHz, CDCl₃) δ 6.47 (1H, t, ²*J* = 53.7 Hz, CHF₂); 6.63 (1H, d, ⁴*J* = 2.2 Hz, H-3); 6.84 (1H, d, ⁴*J* = 2.2 Hz, H-5); 7.49–7.58 (3H, m, H Ph); 7.78 (2H, dd, ³*J* = 8.1 Hz, ⁴*J* = 1.1 Hz, H-2, H-6 Ph). ¹⁹F NMR (471 MHz, CDCl₃) δ 38.3 (d, ²*J* = 53.7 Hz, CF₂H). ¹³C NMR (126 MHz, CDCl₃) δ 109.0 (t, ¹*J*_{CF} = 242.9 Hz, CF₂H); 112.2; 114.4 (t, ³*J*_{CF} = 4.0 Hz, C-3); 126.0 (2C Ar); 129.2 (2C Ar); 130.3; 132.0; 157.0 (t, ²*J*_{CF} = 27.2 Hz, C-2); 163.9; 178.6 (CO). HRMS (ESI) *m*/*z* [M + H]⁺. Calcd for C₁₂H₉F₂O₂: 223.0571. Found: 223.0574.

2-*Phenyl-6*-(1,1,2,2-*tetrafluoroethyl*)-4*H*-*pyran*-4-one (**5k**). Yield 44% (120 mg), yellow powder, mp 125–126 °C. IR (ATR) v 3074, 2924, 1663, 1622, 1452, 1239, 1104, 940. ¹H NMR (500 MHz, CDCl₃) δ 6.10 (1H, tt, ²*J* = 53.1 Hz, ³*J* = 2.7 Hz, CHF₂); 6.77 (1H, d, ⁴*J* = 1.8 Hz, CH); 6.84 (1H, d, ⁴*J* = 1.8 Hz, CH); 7.50–7.60 (3H, m, H Ph); 7.76 (2H, dd, ³*J* = 7.8 Hz, ⁴*J* = 1.4 Hz, H-2, H-6 Ph). ¹⁹F NMR (471 MHz, CDCl₃) δ 26.9 (dt, ²*J*_{HF} = 53.0 Hz, ³*J*_{FF} = 4.0 Hz, CF₂); 41.1 (td, ³*J*_{FF} = 4.0 Hz, ³*J*_{HF} = 2.7 Hz, CF₂H). HRMS (ESI) *m*/*z* [M + H]⁺. Calcd for C₁₃H₉F₄O₂: 273.0539. Found: 273.0542.

2-(1,1,2,2,3,3,4,4-Octafluorobutyl)-6-phenyl-4H-pyran-4-one (5l). Yield 70% (261 mg), paleyellow semi-solid liquid. IR (ATR) v 3047, 1660, 1629, 1602, 1497, 1404, 1118, 944, 767. ¹H NMR (500 MHz, CDCl₃) δ 6.08 (1H, tt, ²*J* = 51.8 Hz, ³*J* = 5.1 Hz, CHF₂); 6.83 (1H, d, ⁴*J* = 2.0 Hz, CH); 6.88 (1H, d, ⁴*J* = 2.0 Hz, CH); 7.51 (2H, dd, ³*J* = 7.9 Hz, ³*J* = 7.3 Hz, H-3, H-5 Ph); 7.57 (1H, tt, ³*J* = 7.3 Hz, ⁴*J* = 1.3 Hz, H-4 Ph); 7.75 (2H, dd, ³*J* = 7.9 Hz, ⁴*J* = 1.3 Hz, H-2, H-6 Ph). ¹⁹F NMR (376 MHz, CDCl₃) δ 24.8 (dm, ²*J*_{HF} = 51.8 Hz, CF₂H); 32.5–32.7 (m, 3-CF₂); 37.75–37.85 (m, 2-CF₂); 43.8 (tt, ³*J*_{FF} = 11.4 Hz, ³*J*_{FF} = 1.7 Hz, 1-CF₂). HRMS (ESI) *m*/*z* [M + H]⁺. Calcd for C₁₅H₉F₈O₂: 373.0475. Found: 373.0479.

3.6. Synthesis of Pyrones 6

General procedure (Method C). A solution of Br₂ (400 mg, 2.5 mmol) in CH₂Cl₂ (4.25 mL) was added to enedione 2 (1 mmol) in CH₂Cl₂ (2.7 mL) under cooling on an ice-bath. After that, the reaction mixture was stirred at room temperature for 15 h, and then the solvent was evaporated without heating. The residue was refluxed in pyridine (3 mL) at 100 °C for 10 h. The excess of pyridine was evaporated under reduced pressure and the product was purified by flash-chromatography (EtOAc). The product was hot-extracted with hexane (3 × 5 mL). The solvent was evaporated until 2 mL of hexane, and the product crystallized from the extract after cooling.

3-Bromo-6-phenyl-2-(trifluoromethyl)-4H-pyran-4-one (**6a**). Yield 73 mg (23%), beige solid, mp 132–133 °C. IR (ATR) v 3069, 1646, 1600, 1451, 1146, 973, 769. ¹H NMR (500 MHz, CDCl₃) δ 6.94 (1H, s, H-5); 7.50–7.57 (2H, m, H-3, H-5 Ph); 7.57–7.62 (1H, m, H-4 Ph); 7.79 (2H, d, ³J = 7.4 Hz, H-2, H-6 Ph). ¹⁹F NMR (471 MHz, CDCl₃) δ 95.6 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 109.3; 116.3; 118.8 (q, ¹J_{CF} = 276.4 Hz, CF₃); 126.0 (2C Ph); 129.3; 129.4 (2C Ph); 132.6; 149.7 (q, ²J_{CF} = 38.0 Hz, C-6); 163.2; 172.8 (CO). Anal. Calcd for C₁₂H₆BrF₃O₂: C 45.17; H 1.90. Found: C 45.36; H 1.86%.

3-Bromo-6-(4-fluorophenyl)-2-(trifluoromethyl)-4H-pyran-4-one (**6b**). Yield 94 mg (28%), beige solid, mp 156–167 °C. IR (ATR) v 1667, 1627, 1556, 1412. ¹H NMR (500 MHz, CDCl₃) δ 6.88 (1H, s, H-5); 7.20–7.28 (2H, m, H-3, H-5 Ar); 7.77–7.85 (2H, m, H-2, H-6 Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ 56.4 (tt, ³*J*_{FH} = 8.2 Hz, ⁴*J*_{FH} = 5.2 Hz, F-Ar); 95.6 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 109.1 (d, ⁶*J*_{CF} = 1.1 Hz, H-5); 116.4 (q, ³*J*_{CF} = 1.1 Hz, C-3); 116.8 (d, ²*J*_{CF} = 22.3 Hz, C-3, C-5 Ar); 118.7 (q, ¹*J*_{CF} = 276.6 Hz, CF₃); 125.5 (d, ⁴*J*_{CF} = 3.4 Hz, C-1 Ar); 128.4 (d, ³*J*_{CF} = 9.1 Hz, C-2, C-6 Ar); 149.6 (q, ²*J*_{CF} = 39.6 Hz, C-2); 162.2; 162.3 (d, ¹*J*_{CF} = 255.4 Hz, C-4 Ar); 172.7 (CO). Anal. Calcd for C₁₂H₅BrF₄O₂: C 42.76; H 1.50. Found: C 42.39; H 1.33%.

3-Bromo-6-(4-chlorophenyl)-2-(trifluoromethyl)-4H-pyran-4-one (**6c**). Yield 120 mg (34%), beige solid, mp 149–150 °C. *Procedure* from tribromide **3c**: Tribromide **3c** (533 mg, 1.0 mmol) was refluxed in pyridine (3 mL) at 100 °C for 10 h. The excess of pyridine was evaporated under reduced pressure, and the product purified by flash-chromatography (EtOAc). The product was hot-extracted with hexane (3×5 mL). The solvent was evaporated until 2 mL of hexane, and the product crystallized from extract after cooling. Yield 36% (127 mg), beige solid, mp 149–150 °C. IR (ATR) v 3069, 1645, 1600, 1577, 1561, 1498, 1451. ¹H NMR (400 MHz, CDCl₃) δ 6.91 (1H, s, H-5); 7.52 (2H, d, ³*J* = 8.7 Hz, H Ar); 7.72 (2H, d, ³*J* = 8.7 Hz, H Ar). ¹⁹F NMR (376 MHz, CDCl₃) δ 95.6 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 109.4 (C-5); 116.5 (C-3); 118.7 (q, ¹*J*_{CF} = 276.5 Hz, CF₃); 127.3 (2C Ar); 127.7 (C Ar); 129.8 (2C Ar); 139.1; 149.7 (q, ²*J*_{CF} = 38.1 Hz, C-2); 162.1; 172.7 (CO). HRMS (ESI) *m*/*z* [M + H]⁺. Calcd for C₁₂H₆BrClF₃O₂: 352.9186. Found: 352.9183.

3-Bromo-6-(3-nitrophenyl)-2-(trifluoromethyl)-4H-pyran-4-one (**6e**). Yield 15 mg (4%), yellowish solid, mp 122–125 °C. IR (ATR) \vee 3074, 3055, 1672, 1647, 1615, 1596, 1532, 1442. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.58 (1H, s, H-5); 7.90 (1H, t, ³*J* = 8.1 Hz, H-5 Ar); 8.39 (1H, ddd, ³*J* = 7.9 Hz, ⁴*J* = 1.7 Hz, ⁴*J* = 0.9 Hz, H-6 Ar); 8.46 (1H, ddd, ³*J* = 8.2 Hz, ⁴*J* = 2.2 Hz, ⁴*J* = 0.8 Hz, H-4 Ar); 8.68 (1H, dd, ⁴*J* = 2.2 Hz, ⁴*J* = 1.7 Hz, H-2 Ar). ¹H NMR (400 MHz, CDCl₃) δ 7.04 (1H, s, H-5); 7.78 (1H, t, ³*J* = 8.8 Hz, H-5 Ar); 8.12 (1H, ddd, ³*J* = 7.9 Hz, ⁴*J* = 1.7 Hz, ⁴*J* = 1.0 Hz, H-6 Ar); 8.45 (1H, ddd, ³*J* = 8.3 Hz, ⁴*J* = 2.2 Hz, ⁴*J* = 1.0 Hz, H-4 Ar); 8.64 (1H, dd, ⁴*J* = 2.2 Hz, ⁴*J* = 1.7 Hz, ⁴*J* = 1.0 Hz, H-6 Ar); 8.45 (1H, ddd, ³*J* = 8.3 Hz, ⁴*J* = 2.2 Hz, ⁴*J* = 1.0 Hz, H-4 Ar); 8.64 (1H, dd, ⁴*J* = 2.2 Hz, ⁴*J* = 1.7 Hz, H-2 Ar). ¹⁹F NMR (376 MHz, CDCl₃) δ 95.6 (s, CF₃). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 110.9; 115.8; 118.6 (q, ¹*J*_{CF} = 277.0 Hz, CF₃); 120.8; 126.5;

131.0; 131.2; 132.4; 148.3; 148.9 (q, ${}^{2}J_{CF}$ = 36.8 Hz, C-2); 160.2; 172.5 (CO). HRMS (ESI) *m*/z [M + H]⁺. Calcd for C₁₂H₆BrF₃NO₄: 363.9427. Found: 363.9429.

3-Bromo-6-(*p*-tolyl)-2-(trifluoromethyl)-4H-pyran-4-one (**6f**). Yield 107 mg (32%), beige solid, mp 170–171 °C. IR (ATR) v 1644, 1608, 1595, 1569, 1511, 1449. ¹H NMR (500 MHz, CDCl₃) δ 2.44 (3H, s, Me); 6.90 (1H, s, H-5); 7.33 (2H, d, *J* = 8.1 Hz, H-3, H-5 Ar); 7.67 (2H, d, *J* = 8.1 Hz, H-2, H-6 Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ 95.6 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 21.5 (CH₃); 111.6 (C-3); 114.6 (q, ³*J*_{CF} = 2.5 Hz, C-5); 118.5 (q, ¹*J*_{CF} = 273.8 Hz, CF₃); 125.9 (2C Ar); 127.0 (C Ar); 130.0 (2C Ar); 143.1(C Ar); 152.3 (q, ²*J*_{CF} = 39.5 Hz, C-6); 164.1 (C-2); 178.0 (CO). HRMS (ESI) *m*/*z* [M + H]⁺. Calcd for C₁₃H₉BrF₃O₂: 332.9733. Found: 332.9737.

3-Bromo-2-(*difluoromethyl*)-6-phenyl-4H-pyran-4-one (**6j**). Yield 84 mg (28%), beige solid, mp 122–123 °C. ¹H NMR (500 MHz, CDCl₃) δ 6.93 (1H, s, H-5); 7.00 (1H, t, ²*J*_{HF} = 52.1 Hz, CHF₂); 7.50–7.61 (3H, m, H Ph); 7.80–7.84 (2H, m, H-2, H-6 Ph). ¹⁹F NMR (376 MHz, CDCl₃) δ 39.3 (d, ²*J*_{HF} = 52.1 Hz, CF₂H). ¹³C NMR (126 MHz, CDCl₃) δ 109.3 (t, ¹*J*_{CF} = 242.3 Hz, CF₂H); 109.5; 116.5 (t, ³*J*_{CF} = 5.3 Hz, C-3); 126.1 (2C Ph); 129.3 (2C Ph); 129.6; 132.4; 152.9 (t, ²*J*_{CF} = 23.9 Hz, C-2); 163.6; 172.9 (CO). HRMS (ESI) m/z [M + H]⁺. Calcd for C₁₃H₁₀F₃O₂: 255.0633. Found: 255.0629.

3-Bromo-6-phenyl-2-(1,1,2,2-tetrafluoroethyl)-4H-pyran-4-one (**6k**). Yield 77 mg (24%), beige solid, mp 122–125 °C. IR (ATR) v 3074, 3002, 1642, 1452, 1383, 1231, 1213, 1083, 975, 842. ¹H NMR (500 MHz, CDCl₃) δ 6.32 (1H, tt, ²*J*_{HF} = 52.8 Hz, *J* = 4.0 Hz, CHF₂); 6.95 (1H, s, H-5); 7.51–7.56 (2H, m, H-3, H-5 Ph); 7.57–7.61 (1H, m, H-4 Ph); 7.75–7.79 (2H, m, H-2, H-6 Ph). ¹⁹F NMR (471 MHz, CDCl₃) δ 26.3 (dt, ³*J*_{FF} = 6.6 Hz, ³*J*_{HF} = 4.1 Hz, CF₂); 44.6 (td, ²*J*_{FF} = 52.8 Hz, ³*J*_{FF} = 6.6 Hz, CF₂H). ¹³C NMR (126 MHz, CDCl₃) δ 108.9 (tt, ¹*J*_{CF} = 254.1 Hz, ²*J*_{CF} = 35.8 Hz, CF₂H); 109.2; 111.4 (tt, ¹*J*_{CF} = 256.9 Hz, ²*J*_{CF} = 28.9 Hz, CF₂); 117.6; 126.0 (2C Ph); 129.4 (2C Ph); 130.5; 132.5; 150.9 (t, ²*J*_{CF} = 27.4 Hz, C-2); 163.6; 172.8 (CO). HRMS (ESI) m/z [M + H]⁺. Calcd for C₁₃H₇BrF₄O₂: 350.9644. Found: 350.9650.

3-Bromo-2-(1,1,2,2,3,3,4,4-octafluorobutyl)-6-phenyl-4H-pyran-4-one (**6**I). Yield 149 mg (33%), beige solid, mp 86–88 °C. IR (ATR) v 3075, 1640, 1499, 1453, 1377, 1145, 943. ¹H NMR (400 MHz, CDCl₃) δ 6.12 (3H, tt, ²J_{HF} = 51.9 Hz, ³J_{HF} = 5.2 Hz, CHF₂); 6.95 (1H, s, H-5); 7.51–7.62 (3H, m, H Ph); 7.74–7.78 (2H, m, H-2, H-6 Ph). ¹⁹F NMR (376 MHz, CDCl₃) δ 24.9 (dm, ²J_{HF} = 51.9 Hz, CF₂H); 32.4 –32.6 (m, 3-CF₂); 38.7–38.8 (m, 2-CF₂); 49.3 (t, ³J_{FF} = 11.6 Hz, 1-CF₂). HRMS (ESI) m/z [M + H]⁺. Calcd for C₁₅H₇BrF₈O₂: 450.9580. Found: 450.9590.

3.7. Synthesis of Fluorinated Azaheterocycles 7-9

2-Phenyl-6-(trifluoromethyl)pyridin-4(1H)-one (7). A solution of pyrone **5a** (120 mg, 0.5 mmol) in EtOH (2 mL), saturated with NH₃ at room temperature, was heated in an autoclave at 100 °C for 8 h. The reaction mixture was diluted with H₂O (10 mL), and the formed precipitate was filtered and recrystallized from EtOH. Yield 84 mg (70%), colorless crystals, mp 133–134 °C. IR (ATR) v 1614, 1579, 1481, 1427, 1460, 1429. ¹H NMR (400 MHz, DMSOd₆) δ pyridinol form (96%): 7.05 (1H, s, H-3); 7.25 (1H, s, H-5); 7.39–7.48 (3H, m, H Ph); 7.91 (2H, d, *J* = 6.8 Hz, H-2, H-6 Ph); pyridone form (4%): 6.87 (1H, d, ⁴*J* = 2.0 Hz, H-3); 6.84 (1H, d, ⁴*J* = 2.0 Hz, H-5); 7.39–7.48 (3H, m, H Ph); 7.87–7.94 (2H, m, H-2, H-6 Ph); the signals from NH and OH were not observed due to the fast exchange with water. ¹⁹F NMR (376 MHz, CDCl₃) δ pyridone form (4%): 93.4 (s, CF₃); pyridinol form (96%): 93.6 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 108.3 Hz, 111.2 Hz, 121.2 (q, ¹*J*_{CF} = 274.4 Hz, CF₃); 127.1 (2C Ph); 128.9 (2C Ph); 130.0 Hz, 137.2 Hz, 148.1 Hz, 158.9 Hz, 166.5. Anal. Calcd for C₁₂H₈F₃NO: C 60.26; H 3.37; N 5.86. Found: C 60.35; H 3.26; N 5.84%.

1-Phenyl-3-(4-(trifluoromethyl)-1H-1,2,3-triazol-5-yl)propane-1,3-dione (8). To a solution of pyrone **5a** (96 mg, 0.4 mmol) in DMSO (1 mL), NaN₃ (29 mg, 0.44 mmol) was added, and the mixture was stirred at 115–120 °C for 30 min. The reaction was then diluted with aqueous HCl (10 mL, 0.1 M), and the formed precipitate was filtered and recrystallized

from toluene. Yield 65 mg (55%), pale-brown plates, mp 189–190 °C. IR (ATR) v 3268 (NH), 1600, 1575, 1535, 1492, 1460, 1429. ¹H NMR (400 MHz, DMSO- d_6) δ enol form (82%): 7.19 (1H, s, 2-CH); 7.59 (2H, t, *J* = 7.6 Hz, H-3, H-5 Ph); 7.68 (1H, t, *J* = 7.4 Hz, H-4 Ph); 8.05 (2H, d, *J* = 7.4 Hz, H-2, H-6 Ph); 14.70–17.9 (2H, broad s, NH, OH); keto form (18%): 4.85 (2H, s, CH₂); 7.58 (2H, t, *J* = 7.4 Hz, H-3, H-5 Ph); 7.70 (1H, t, *J* = 7.4 Hz, H-4 Ph); 8.01 (2H, d, *J* = 7.4 Hz, H-2, H-6 Ph); 14.70–17.9 (1H, broad s, NH). ¹⁹F NMR (376 MHz, DMSO- d_6) δ keto form (18%): 102.2 (s, CF₃); enol form (82%): 103.2 (s, CF₃). ¹³C NMR (126 MHz, DMSO- d_6) δ enol form: 94.9 (CH=); 120.7 (q, ¹*J*_{CF} = 268.5 Hz, CF₃); 127.2 (2C Ar); 129.1 (2C Ar); 133.2 (C Ar); 136.2 (q, ²*J*_{CF} = 40.1 Hz, C-CF₃); 140.9 (C Ar); 179.6; 182.2; keto form: 50.7 (CH₂); 120.2 (q, ¹*J*_{CF} = 267.1 Hz, CF₃); 128.5 (2C Ar); 128.9 (2C Ar); 133.9 (C Ar); 136.0 (C Ar); 136.2 (q, ²*J*_{CF} = 40.5 Hz, C-CF₃); 142.4 (C Ar); 187.9 (CO); 194.8 (CO). Anal. Calcd for C₁₂H₈F₃N₃O₂: C 50.89; H 2.85; N 14.84. Found: C 50.90; H 2.78; N 14.85%.

(*E*)-1,5-*Diphenyl*-3-(3,3,3-*trifluoro*-2-(2-*phenylhydrazono*)*propyl*)-1*H*-*pyrazole* (9). A mixture of pyrone **5a** (120 mg, 0.5 mmol) and phenylhydrazine (270 mg, 2.5 mmol) was heated at 120 °C for 3 h. The reaction mixture was cooled to room temperature, treated with 1M HCl solution (10 mL), the formed precipitate was filtered and recrystallized from EtOH. Yield 65 mg (55%), colorless crystals, mp 171–173 °C. IR (ATR) v 3267 (NH), 1605 (C=N), 1543, 1500, 1457. ¹H NMR (500 MHz, CDCl₃) δ 3.84 (2H, s, H-3); 6.40 (1H, s, H-5); 6.91 (1H, t, *J* = 7.3 Hz, H-4 Ph); 7.11 (2H, d, *J* = 7.8 Hz, H-2, H-6 Ph); 7.19 (2H, dd, ³*J* = 7.7 Hz, ⁴*J* = 1.5 Hz, H-2, H-6 Ph); 7.22–7.38 (3H, m, H Ph); 9.99 (1H, s, NH). ¹⁹F NMR (376 MHz, CDCl₃) δ 92.8 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 24.6; 107.2; 113.5 (2C); 121.4; 121.94 (q, ¹*J*_{CF} = 272.0 Hz, CF₃); 125.1 (2C); 127.8; 128.5 (2C); 128.6; 128.7 (2C); 128.78 (q, ²*J*_{CF} = 33.9 Hz, C=N); 129.0 (2C); 129.2 (2C); 129.8; 139.6; 144.1; 144.8; 147.1. Anal. Calcd for C₂₄H₁₉F₃N₄: C 68.56; H 4.56; N 13.33. Found: C 68.42; H 4.38; N 13.34%.

Supplementary Materials: The following are available online, Scheme S1. Reaction of (3Z,5E)-6-(4-(dimethylamino)phenyl)-1,1,1-trifluoro-4-hydroxyhexa-3,5-dien-2-one with Br2 in benzene; Table S1. Composition of reaction mixtures of bromination of enediones 2; Table S2. Characteristic chemical shifts in 1H and 19F NMR spectra of compounds 3; Table S3. Characteristic chemical shifts in 1H and 19F NMR spectra of compounds 4; Table S4. Characteristic chemical shifts in 1H and 19F NMR spectra of dihydropyrone forms of 3; Table S5. Characteristic chemical shifts in 1H and 19F NMR spectra of dihydropyrone forms of 4; full 1H, 19F, and 13C NMR spectra of all synthesized compounds.

Author Contributions: Conceptualization and methodology were provided by V.Y.S., S.A.U. and D.L.O. conceived and designed the experiments. The experimental work was conducted by D.I.N., D.K.M., N.A.N., and S.A.U. S.A.U. and D.L.O. analyzed the results. S.A.U. studied and systemized the NMR data. V.Y.S. and D.L.O. wrote the paper. Project administration and funding acquisition were carried out by V.Y.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Russian Science Foundation, grant number 18-13-00186.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article and Supplementary Materials.

Acknowledgments: Analytical studies were carried out using equipment at the Center for Joint Use 'Spectroscopy and Analysis of Organic Compounds' at the Postovsky Institute of Organic Synthesis of the Russian Academy of Sciences (Ural Branch) and the Laboratory of Complex Investigations and Expert Evaluation of Organic Materials of the Center for Joint Use at the Ural Federal University. Authors would like to thank Artem Chudinov for his help in the work.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

- 1. Singh, K.S. Pyrone-derived marine natural products: A review on isolation, bio-activities and synthesis. *Curr. Org. Chem.* 2020, 24, 354–401. [CrossRef]
- Rukachaisirikul, V.; Kannai, S.; Klaiklay, S.; Phongpaichit, S.; Sakayaroj, J. Rare 2-phenylpyran-4-ones from the seagrass-derived fungi Polyporales PSU-ES44 and PSU-ES83. *Tetrahedron* 2013, *69*, 6981–6986. [CrossRef]
- 3. Zhang, Y.; Zhu, T.; Fang, Y.; Liu, H.; Gu, Q.; Zhu, W. Carbonarones A and B, new bioactive *γ*-pyrone and *α*-pyridone derivatives from the marine-derived fungus *Aspergillus carbonarius*. *J. Antibiot.* **2007**, *60*, 153–157. [CrossRef] [PubMed]
- 4. Ola, A.R.B.; Thomy, D.; Lai, D.; BroJz-Oesterhelt, H.; Proksch, P. Inducing secondary metabolite production by the endophytic Fungus *Fusarium tricinctum* through coculture with *Bacillus subtilis*. J. Nat. Prod. **2013**, 76, 2094–2099. [CrossRef] [PubMed]
- 5. Kunze, B.; Jansen, R.; Pridzun, L.; Jurkiewicz, E.; Hunsmann, G.; Höfle, G.; Reichenbach, H. Phenoxan, a new oxazole-pyrone from myxobacteria: Production, antimicrobial activity and its inhibition of the electron transport in complex I of the respiratory chain. *J. Antibiot.* **1992**, *45*, 1549–1552. [CrossRef]
- 6. Bejcek, L.P.; Murelli, R.P. Oxidopyrylium [5 + 2] cycloaddition chemistry: Historical perspective and recent advances (2008–2018). *Tetrahedron* **2018**, *74*, 2501–2521. [CrossRef]
- 7. Zirak, M.; Eftekhari-Sis, B. Kojic acid in organic synthesis. Turk. J. Chem. 2015, 39, 439–496. [CrossRef]
- 8. Zhang, L.; Cao, T.; Jiang, H.; Zhu, S. Deconstructive reorganization: De Novo synthesis of hydroxylated benzofuran. *Angew. Chem. Int. Ed.* **2020**, *59*, 4670–4677. [CrossRef]
- Obydennov, D.L.; Khammatova, L.R.; Steben'kov, V.D.; Sosnovskikh, V.Y. Synthesis of novel polycarbonyl Schiff bases by ring-opening reaction of ethyl 5-acyl-4-pyrone-2-carboxylates with primary mono- and diamines. *RSC Adv.* 2019, *9*, 40072–40083. [CrossRef]
- 10. Schreiner, E.; Richter, F.; Nerdinger, S. Development of synthetic routes to dolutegravir. Top. Heterocycl. Chem. 2016, 44, 187–208.
- 11. Guo, Z.; Zhu, W.; Tian, H. Dicyanomethylene-4*H*-pyranchromophores for OLED emitters, logic gates and optical chemosensors. *Chem. Commun.* **2012**, *48*, 6073–6084. [CrossRef] [PubMed]
- 12. Obydennov, D.L.; Suslova, A.I.; Sosnovskikh, V.Y. Synthesis and some chemical properties of 2-cyano-4-pyrone. *Chem. Heterocycl. Compd.* **2020**, *56*, 173–179. [CrossRef]
- 13. Obydennov, D.L.; Simbirtseva, A.E.; Piksin, S.E.; Sosnovskikh, V.Y. 2,6-Dicyano-4-pyrone as a novel and multifarious building block for the synthesis of 2,6-bis(hetaryl)-4-pyrones and 2,6-bis(hetaryl)-4-pyridinols. *ACS Omega* 2020, *5*, 33406–33420. [CrossRef]
- Obydennov, D.L.; Sosnovskikh, V.Y. The reaction of 6-substituted 4-pyrone-2-carboxylic acids with *o*-phenylenediamine. Synthesis and structure of 3-(1*H*-1,5-benzodiazepin-2(3*H*)-ylidenemethyl)quinoxalin-2(1*H*)-ones. *Chem. Heterocycl. Compd.* 2015, 51, 281–290. [CrossRef]
- Obydennov, D.L.; Khammatova, L.R.; Eltsov, O.S.; Sosnovskikh, V.Y. A chemo- and regiocontrolled approach to bipyrazoles and pyridones via the reaction of ethyl 5-acyl-4-pyrone-2-carboxylates with hydrazines. *Org. Biomol. Chem.* 2018, *16*, 1692–1707. [CrossRef]
- 16. Obydennov, D.L.; Usachev, B.I.; Sosnovskikh, V.Y. Reactions of 2-mono- and 2,6-disubstituted 4-pyrones with phenylhydrazine as general method for the synthesis of 3-(*N*-phenylpyrazolyl)indoles. *Chem. Heterocycl. Compd.* **2015**, *50*, 1388–1403. [CrossRef]
- Politanskaya, L.; Selivanova, G.A.; Panteleeva, E.V.; Tretyakov, E.V.; Platonov, V.E.; Nikul'Shin, P.V.; Vinogradov, A.S.; Zonov, Y.V.; Karpov, V.M.; Mezhenkova, T.V.; et al. Organofluorine chemistry: Promising growth areas and challenges. *Russ. Chem. Rev.* 2019, 88, 425–569. [CrossRef]
- 18. Usachev, B.I. 2-(Trifluoromethyl)-4*H*-pyran-4-ones: Convenient, available and versatile building-blocks for regioselective syntheses of trifluoromethylated organic compounds. *J. Fluor. Chem.* **2015**, *172*, 80–91. [CrossRef]
- 19. Usachev, S.A.; Sosnovskikh, V.Y. Synthesis of *γ*-pyrone precursors by condensation of acetyl ketene dithioacetals with ethyl polyfluorocarboxylates and diethyl oxalate. *Chem. Heterocycl. Compd.* **2016**, *52*, 1005–1011. [CrossRef]
- Yeates, C.L.; Batchelor, J.F.; Capon, E.C.; Cheesman, N.J.; Fry, M.; Hudson, A.T.; Pudney, M.; Trimming, H.; Woolven, J.; Bueno, J.M.; et al. Synthesis and structure–activity relationships of 4-pyridones as potential antimalarials. *J. Med. Chem.* 2008, *51*, 2845–2852. [CrossRef] [PubMed]
- Tyvorskii, V.I.; Bobrov, D.N.; Kulinkovich, O.G.; Aelterman, W.; de Kimpe, N. Synthesis of 3-(trifluoromethyl)benzo[c][1,6]naphthyridines from substituted 4H-pyran-4-ones via 4-amino-5-aryl-2-(trifluoromethyl)pyridines. *Tetrahedron* 2000, 56, 7313–7318. [CrossRef]
- 22. Büttner, S.; Desens, W.; Michalik, D.; Langer, P. Synthesis and structures of fluoroalkylated triketides. *Eur. J. Org. Chem.* 2011, 6663–6669. [CrossRef]
- 23. Serdyuk, R.N.; Sizov, A.Y.; Ermolov, A.F. Polyfluoroalkylthiotrifluoroacetylketenes. *Rus. Chem. Bull.* 2003, 52, 1854–1858. [CrossRef]
- 24. Boivin, J.; El Kaima, L.; Zarda, S.Z. Trifluoromethyl ketones from carboxylic acids. Part II. A versatile access to trifluoromethylated heterocycles. *Tetrahedron* **1995**, *51*, 2585–2592. [CrossRef]
- Krasnykh, O.P.; Aleksandrov, G.G.; Karpenko, N.S.; Filyakova, V.I.; Charushin, V.N. Formation of fluoroalkyl-containing pyran-4one in the reaction of lithium 4,4,4-trifluoro-1-phenylbutane-1,3-dionate with oxalyl chloride. *Rus. Chem. Bull.* 2007, 56, 178–180. [CrossRef]
- 26. Usachev, B.I.; Obydennov, D.L.; Röschenthaler, G.-V.; Sosnovskikh, V.Y. 2-Cyano-6-(trifluoromethyl)-4-pyran-4-one: A novel versatile CF₃-containing building block. *J. Fluor. Chem.* **2012**, *137*, 22–26. [CrossRef]

- 27. Sosnovskikh, V.Y. Synthesis and reactions of halogen-containing chromones. Russ. Chem. Rev. 2003, 72, 489–516. [CrossRef]
- Sosnovskikh, V.Y.; Korotaev, V.Y.; Chizhov, D.L.; Kutyashev, I.B.; Yachevskii, D.S.; Kazheva, O.N.; Dyachenko, O.A.; Charushin, V.N. Reaction of polyhaloalkyl-substituted chromones, pyrones, and furanones with salicylaldehydes as a direct route to fused 2*H*-chromenes. *J. Org. Chem.* 2006, *71*, 4538–4543. [CrossRef] [PubMed]
- 29. Liu, W.; Fang, L.; Wan, Y.; Zhang, J.; Deng, G.; Wang, J. Synthesis of 2-cyclopropyl-4-pyrones and 5-cyclopropyl-2-alkylene-3(2*H*)furanones based on tandem cyclization-cyclopropanation strategy. *Tetrahedron* **2019**, *75*, 855–861. [CrossRef]
- Wang, F.; Lu, S.; Chen, B.; Zhou, Y.; Yang, Y.; Deng, G. Regioselective reversal in the cyclization of 2-diazo-3,5-dioxo-6-ynoates (ynones, ynamide): Construction of γ-pyrones and 3(2*H*)-furanones starting from identical materials. *Org. Lett.* 2016, 18, 6248–6251. [CrossRef] [PubMed]
- 31. Solas, M.; Muñoz, M.A.; Suárez-Pantiga, S.; Sanz, R. Regiodivergent hydration–cyclization of diynones under gold catalysis. *Org. Lett.* **2020**, *22*, 7681–7687. [CrossRef]
- 32. Fürstner, A. Gold catalysis for heterocyclic chemistry: A representative case study on pyrone natural products. *Angew. Chem. Int. Ed.* **2018**, *57*, 4215–4233. [CrossRef]
- Zhang, J.; Deng, G.; Wang, J. Diastereoselective synthesis of 2-(1,3-dioxolanes-4-yl)-4H-pyran-4-ones from 2-diazo-3,5-dioxo-6ynoates (sulfones) and aldehydes based on tandem cyclization-cycloaddition strategy. *Eur. J. Org. Chem.* 2019, 2019, 3979–3986. [CrossRef]
- 34. Usachev, B.I.; Obydennov, D.L.; Kodess, M.I.; Röschenthaler, G.-V.; Sosnovskikh, V.Y. New derivatives of 6-phenylcomanic acid. *Rus. Chem. Bull.* **2009**, *58*, 1248–1252. [CrossRef]
- 35. Soliman, G.; Rateb, L. Synthesis of heterocyclic compounds from δ-unsaturated 1:3-diketo-esters. *J. Chem. Soc.* **1956**, 3663–3668. [CrossRef]
- 36. Clark, B.P.; Ross, W.J.; Todd, A. 6-Substituted Pyranone Compounds and Their Use as Pharmaceuticals. US Patent 4471129, 1984.
- 37. Borsche, W.; Peter, W. Über eine neue y-Pyronsynthese. Justus Liebigs Ann. Chem. 1927, 53, 148–162. [CrossRef]
- Pashkevich, K.L.; Khomutov, O.G. Synthesis of polyfluoroalkyl-containing dienones. *Rus. Chem. Bull.* 1996, 45, 2169–2171. [CrossRef]
- Kim, E.; Felouat, A.; Zaborova, E.; Ribierre, J.-C.; Wu, J.W.; Senatore, S.; Matthews, C.; Lenne, P.-F.; Baffert, C.; Karapetyan, A.; et al. Borondifluoride complexes of hemicurcuminoids as bio-inspired push-pull dyes for bioimaging. *Org. Biomol. Chem.* 2016, 14, 1311–1324. [CrossRef]
- 40. Sosnovskikh, V.Y.; Ovsyannikov, I.S. Condensation of trichloro- and trfluoroacetonitriles with mesityl oxide and arylideneacetones. *Russ. J. Org. Chem.* **1993**, *29*, 214–219.
- 41. Leng, D.J.; Black, C.M.; Pattison, G. One-pot synthesis of difluoromethyl ketones by a difluorination/fragmentation process. *Org. Biomol. Chem.* **2016**, *14*, 1531–1535. [CrossRef]
- 42. Kobelevskaya, V.A.; Popov, A.V.; Zinchenko, S.V.; Rulev, A.Y. Chemoselective bromination of dienoates. *Eur. J. Org. Chem.* 2020, 2020, 5544–5550. [CrossRef]
- Usachev, S.A.; Usachev, B.I.; Eltsov, O.S.; Sosnovskikh, V.Y. Synthesis of isomerically pure 3-(5-trifluoromethyl-1,2,3-triazol-4-yl)cinnamic acid derivatives via the reaction of 4-aryl-6-trifluoromethyl-2-pyrones with sodium azide. *Tetrahedron* 2014, 70, 8863–8871. [CrossRef]
- 44. He, Y.-H.; He, T.; Guo, J.-T.; Li, R.; Xiang, Y.; Yang, D.-C.; Guan, Z. Enzyme-catalyzed domino reaction: Efficient construction of spirocyclic oxindole skeleton using porcine pepsin. *Catal. Sci. Technol.* **2016**, *6*, 2239–2248. [CrossRef]